Cynata Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume8,439 shs
Market Capitalization$44.48 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CYYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cynata Therapeutics logo

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.52 out of 5 stars

Medical Sector

1570th out of 2,105 stocks

Sanitary Paper Products Industry

1st out of 1 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cynata Therapeutics (OTCMKTS:CYYNF) Frequently Asked Questions

Is Cynata Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cynata Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cynata Therapeutics stock.
View analyst ratings for Cynata Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cynata Therapeutics?

Wall Street analysts have given Cynata Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cynata Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Cynata Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Cynata Therapeutics' stock was trading at $0.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYYNF shares have decreased by 38.0% and is now trading at $0.4650.
View which stocks have been most impacted by COVID-19

Who are Cynata Therapeutics' key executives?

Cynata Therapeutics' management team includes the following people:
  • Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 63, Pay $351.71k)
  • Dr. Kilian Kelly, Chief Operating Officer
  • Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 58, Pay $108.42k)
  • Dr. Suzanne Lipe, VP of Alliance Management (Age 71, Pay $168.58k)

Who are some of Cynata Therapeutics' key competitors?

What is Cynata Therapeutics' stock symbol?

Cynata Therapeutics trades on the OTCMKTS under the ticker symbol "CYYNF."

How do I buy shares of Cynata Therapeutics?

Shares of CYYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cynata Therapeutics' stock price today?

One share of CYYNF stock can currently be purchased for approximately $0.47.

How much money does Cynata Therapeutics make?

Cynata Therapeutics has a market capitalization of $44.48 million.

What is Cynata Therapeutics' official website?

The official website for Cynata Therapeutics is www.cynata.com.

How can I contact Cynata Therapeutics?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.